@article {CROSSLEY1699, author = {RACHEL A. CROSSLEY and ALYSSA MATZ and TERRY DEW and ASHLEY KALINAUSKAS and NICOLE FAUCETTE and BRAD POFF and LAWRENCE K. SILBART and MARK A. SUCKOW}, title = {Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model}, volume = {39}, number = {4}, pages = {1699--1703}, year = {2019}, doi = {10.21873/anticanres.13275}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. Materials and Methods: An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. Results: A small number (12\%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Conclusion: Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/39/4/1699}, eprint = {https://ar.iiarjournals.org/content/39/4/1699.full.pdf}, journal = {Anticancer Research} }